CBAY News and Press, CymaBay Therapeutics Inc. From 05/11/22

NEWARK, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that multiple Phase 2 and Phase 3 st...

NEWARK, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audi...

Gainers: Avadel Pharmaceuticals  (AVDL) +31%. AlloVir (ALVR) +7%. Redbox Entertainment  (RDBX) +6%. CymaBay Therapeutics  (CBAY) +5%. Harpoon Therapeutics. (HARP) +5%. Losers: Protagonist Therapeutics (PTGX) -41%. Nkarta (NKTX) -6%. Provention Bio (PRVB...

Gainers: Evelo Biosciences, Inc. (EVLO) +5%. CymaBay Therapeutics Inc. (CBAY) +5%. Allakos Inc. (ALLK) +5%. Diversified Healthcare Trust (DHC) +4%. Angi Inc. (ANGI) +3%. Losers: Dogness (International) Corporation (DOGZ) -5%. MaxCyte, Inc. (MXCT) -4%. FTC Solar, Inc. (FTCI...

CymaBay Therapeutics Inc. (NASDAQ:CBAY) traded today at a new 52-week high of $15.58. So far today approximately 116.5 million shares have been exchanged, as compared to an average 30-day volume of 401,000 shares. CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company. It...

CymaBay Therapeutics (NASDAQ:CBAY) announced results from the Phase 2, 52-week study of Seladelpar in patients with primary biliary cholangitis (PBC). The company said the mid-stage study examined the efficacy and safety of seladelpar in adults with PBC who were receiving or intolerant to fir...

NEWARK, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that results from the Phase 2, 52-...

CymaBay Therapeutics, Inc. (CBAY) Q4 2021 Earnings Conference Call March 17, 2022 16:30 ET CompanyParticipants Paul Quinlan - General Counsel Sujal Shah - President & Chief Executive Officer Daniel Menold - Vice President of Finance Charles McWherter - Chief Scientific Officer Dennis Kim ...

Image source: The Motley Fool. CymaBay Therapeutics Inc. (NASDAQ: CBAY) Q4 2021 Earnings Call Mar 17, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: CymaBay Therapeutics Inc. (CBAY) Q4 2021 Earnings Call Transcript...

NEWARK, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of Dr. Éric Lefebvre to it...